TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03632369

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized xenon-129 MRI
Description: Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized xenon-129 MRI
Description: Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
Study: NCT01298804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Education and Activated Referral to Care
Description: The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time.
Study: NCT01341275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: 10 ug dose, one-time administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: 10 ug dose, one-time administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: 20 ug dose, one-time administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: 20 ug dose, one-time administration
Study: NCT03303235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylergonovine
Description: IV vs IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Description: IV vs IM
Study: NCT03411161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy (S81694 + paclitaxel) phase I
Description: Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (IV) at 80 mg/m²/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy (S81694 + paclitaxel) phase II
Description: S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
Study: NCT03875508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab to be injected subcutaneously (SC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Single dose pre-filled autoinjector containing risankizumab for SC injection
Study: NCT04558229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Standardized Counseling
Description: Research staff will follow a script designed to give unbiased, medically accurate information regarding bleeding changes that may occur with use of a contraceptive ENG implant.
Study: NCT02643524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Counseling
Description: Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
Study: NCT01093404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus aspiration
Description: Aspiration of thrombus material before angioplasty
Study: NCT04292756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Description: Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent angiography
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent angiography
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Refractometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Refractometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmoscopy
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmoscopy
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OKT
Description: Ophthalmic examination
Study: NCT01727193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
Study: NCT00763087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weightbearing exercise
Description: All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonweightbearing exercise
Description: All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: nonexercising control
Description: All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
Study: NCT01037699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH: Follicle Stimulating Hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH: Follicle Stimulating Hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)
Study: NCT01276860

Intervention type: DEVICE
Group type: OTHER
Intervention: Psychomotor Vigilance Testing
Description: The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
Study: NCT01093404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Aspiration of thrombus material before angioplasty
Study: NCT02092090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction
Description: Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
Study: NCT03178058

Intervention type: OTHER
Intervention: Questionaire
Description: Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting).
Study: NCT04458714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortoiliac angioplasty
Description: In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortoiliac angioplasty
Description: In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
Study: NCT02561130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Dose is titrated to achieve fasting normoglycemia
Study: NCT00657709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)
Description: One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
Study: NCT02561130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Dose is titrated to 1 g bid or maximal tolerated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga
Description: Dose is titrated to 10 mg po daily or maximal tolerated dose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
Study: NCT02405416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrahepatic inferior vena cava clamping
Description: Infrahepatic inferior vena cava is clamped in hepatectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective hepatic vascular exclusion
Description: Selected major hepatic vein is clamped in hepatectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal triad clamping
Description: Portal triad are clamped in hepatectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal triad clamping
Description: Portal triad are clamped in hepatectomy.
Study: NCT00203203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramyocardial Injection of stem cells via NOGA Mapping
Description: Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Control, then Stem Cell Therapy
Description: Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
Study: NCT03128697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satiating diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satiating diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Study: NCT00657709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)
Description: One dose of rMenB concomitantly with the routinely administered infant vaccines
Study: NCT00785486

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam Alone
Description: Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Qualaquin (quinine) alone steady state
Description: Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and Qualaquin at steady state
Description: On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
Study: NCT04458064

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA i gel
Description: insertion of LMA for maintaining airway during anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA i gel
Description: insertion of LMA for maintaining airway during anesthesia
Study: NCT00677495

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: Gluten-free diet
Study: NCT02422433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule Marking
Description: Marking and imaging of the esophagus using the OFDI Capsule and system.
Study: NCT02193594

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy
Description: The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical D2 total gastrectomy
Description: Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical D2 total gastrectomy
Description: Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
Study: NCT03440879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Patients currently treated with Zoladex
Study: NCT02141516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Description: 2 doses of vaccine 2 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Description: 2 doses of vaccine 2 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV
Description: 2 doses of vaccine 2 months apart
Study: NCT02164396

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle Lens
Description: Spectacle Lens Only

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Soft Contact Lens
Description: subject's own contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: senofilcon A or narafilcon A
Study: NCT02188576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose TXA
Study: NCT01690767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Description: Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Health Care Lubricating Jelly
Description: Non-medicinal lubrication gel
Study: NCT02678039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
Study: NCT02364310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baroreceptor stimulation with Barostim Neo TM
Study: NCT02149433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03945877

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT01486563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Hydroxyethyl starch 130/0,4)
Description: 7,5 ml/kg in the first hour and then 5 ml/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9 mg/ml
Description: 7,5 ml/kg in the first hour and then 5 ml/kg